Autolus Therapeutics plc (NASDAQ:AUTL) Receives $9.52 Consensus Price Target from Brokerages

Autolus Therapeutics plc (NASDAQ:AUTL) has earned a consensus rating of “Buy” from the six brokerages that are covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have covered the stock in the last year is $9.52.

AUTL has been the topic of several research reports. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, January 13th. Wells Fargo & Company decreased their price target on shares of Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a research note on Friday.

Autolus Therapeutics Stock Up 1.5 %

Shares of NASDAQ AUTL opened at $1.70 on Friday. The business’s 50 day moving average price is $2.02 and its two-hundred day moving average price is $2.90. The company has a market cap of $452.36 million, a PE ratio of -1.40 and a beta of 2.07. Autolus Therapeutics has a twelve month low of $1.56 and a twelve month high of $6.60.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.12. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $2.98 million. As a group, research analysts anticipate that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Virtus ETF Advisers LLC increased its position in Autolus Therapeutics by 29.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company’s stock worth $62,000 after acquiring an additional 6,081 shares during the period. Daiwa Securities Group Inc. grew its position in shares of Autolus Therapeutics by 55.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company’s stock worth $56,000 after purchasing an additional 8,479 shares in the last quarter. Bellevue Group AG increased its holdings in shares of Autolus Therapeutics by 27.7% during the third quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock worth $151,000 after purchasing an additional 9,000 shares during the period. State Street Corp raised its position in shares of Autolus Therapeutics by 1.7% in the third quarter. State Street Corp now owns 606,544 shares of the company’s stock valued at $2,202,000 after buying an additional 10,401 shares in the last quarter. Finally, Barclays PLC raised its position in shares of Autolus Therapeutics by 1,094.3% in the fourth quarter. Barclays PLC now owns 11,859 shares of the company’s stock valued at $28,000 after buying an additional 10,866 shares in the last quarter. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.